AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26450000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure >90 mm Hg, aspirin ≤81 mg, and international normalized ratio >3.0
Number of subjects: 382
Study 24119597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral maxillary sinus saline irrigation for 2 months after ESS
Number of subjects: 30
Study 24119597 — intervention group
Group type: COMPARATOR
Intervention: Control group (no irrigation)
Number of subjects: 30
Study 20465357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cortisol infusion before retrieval testing
Number of subjects: 0
Study 20465357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19552867 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60‐120 mg once daily
Number of subjects: 288
Study 19552867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 17377086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg + Ondansetron 4 mg (Group D4/O4)
Number of subjects: 614
Study 17377086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg + Ondansetron 2 mg (Group D4/O2)
Number of subjects: 614
Study 17377086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg + Ondansetron 4 mg (Group D2/O4)
Number of subjects: 614
Study 17377086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg + Ondansetron 2 mg (Group D2/O2)
Number of subjects: 614
Study 17377086 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (D4/O4, D4/O2, D2/O4, D2/O2)
Number of subjects: 614
Study 17377086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg (Groups D2/O4 and D2/O2)
Number of subjects: 614
Study 15000732 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (1.2 million units as a single dose)
Number of subjects: 161
Study 15000732 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (600 mg every 6 h for 10 days)
Number of subjects: 161
Study 15000732 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl penicillin (2 million units every 4 h for 10 days)
Number of subjects: 161
Study 15000732 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin
Number of subjects: 161
Study 15000732 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 161
Study 15000732 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl penicillin
Number of subjects: 161
Study 11772897 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based stress management training
Number of subjects: 108
Study 9665189 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AraC (3.0 g/m2 for patients younger than 60 years; 1.0 g/m2 for older patients)
Number of subjects: 186
Study 9665189 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose AraC (1.0 g/m2 for patients younger than 60 years; 0.5 g/m2 for older patients)
Number of subjects: 186
Study 9665189 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AraC in refractory AML subgroup
Number of subjects: 186
Study 9665189 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose AraC in older patients
Number of subjects: 186
Study 8555377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FXT)
Number of subjects: 34
Study 8555377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8555377 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) breakfast
Number of subjects: 34
Study 8555377 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich (PROT) breakfast
Number of subjects: 34
Study 2713622 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral siliconised latex catheter
Number of subjects: 205
Study 2713622 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic siliconised latex catheter
Number of subjects: 205
Study 709793 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder administration of beclomethasone dipropionate (100 micrograms, 4 doses)
Number of subjects: 37
Study 709793 — intervention group
Group type: COMPARATOR
Intervention: Aerosol administration of beclomethasone dipropionate (100 micrograms, 4 doses)
Number of subjects: 37
Study 31957152 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil 5%
Number of subjects: 22
Study 31957152 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil 2%
Number of subjects: 22
Study 31957152 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral finasteride 1 mg daily
Number of subjects: 22
Study 31957152 — intervention group
Group type: COMPARATOR
Intervention: Control lotion (1 mL/d)
Number of subjects: 22
Study 30404088 — intervention group
Group type: EXPERIMENTAL
Intervention: SUTMEK-milk
Number of subjects: 15
Study 30404088 — intervention group
Group type: COMPARATOR
Intervention: SUTMEK-placebo
Number of subjects: 15
Study 30404088 — intervention group
Group type: COMPARATOR
Intervention: SUTMEK-milk or SUTMEK-placebo
Number of subjects: 15
Study 28385735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with prior exercise (45 min leg cycling)
Number of subjects: 15
Study 28385735 — intervention group
Group type: COMPARATOR
Intervention: Sitting without prior exercise
Number of subjects: 15
Study 28385735 — intervention group
Group type: COMPARATOR
Intervention: Standing without prior exercise
Number of subjects: 15
Study 25418979 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 0
Study 25418979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23385271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/d for 24 weeks
Number of subjects: 212
Study 23385271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 21115010 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin/NSAID use after blood collection
Number of subjects: 32826
Study 21115010 — intervention group
Group type: COMPARATOR
Intervention: Highest quartile of plasma levels of sTNFR-2
Number of subjects: 32826
Study 21115010 — intervention group
Group type: COMPARATOR
Intervention: Plasma levels of CRP and IL-6
Number of subjects: 32826
Study 19214525 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 16
Study 19214525 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 17855283 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching for six hours a day
Number of subjects: 97
Study 17855283 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching for twelve hours a day
Number of subjects: 97
Study 17855283 — intervention group
Group type: COMPARATOR
Intervention: Patching for less than three hours a day
Number of subjects: 97
Study 14986556 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intranasal butorphanol (single dose)
Number of subjects: 24
Study 14986556 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intranasal butorphanol (single dose)
Number of subjects: 24
Study 14986556 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intranasal butorphanol (multiple doses every six hours for seven doses)
Number of subjects: 24
Study 14986556 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intranasal butorphanol (multiple doses every six hours for seven doses)
Number of subjects: 24
Study 14986556 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg and 2 mg intranasal butorphanol
Number of subjects: 24
Study 14986556 — intervention group
Group type: COMPARATOR
Intervention: 2 mg vs 1 mg intranasal butorphanol (single dose)
Number of subjects: 24
Study 11687362 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR) implantation
Number of subjects: 78
Study 11687362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CTR)
Number of subjects: 78
Study 9270151 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid publicity on ethnic radio during three discrete periods between 1992 and 1994
Number of subjects: 0
Study 9270151 — intervention group
Group type: COMPARATOR
Intervention: Control group (areas with low proportion of women of non-English-speaking background)
Number of subjects: 0
Study 7870219 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with cisplatin
Number of subjects: 62
Study 7870219 — intervention group
Group type: COMPARATOR
Intervention: Second/third-line chemotherapy with cisplatin
Number of subjects: 62
Study 7870219 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus CDDP
Number of subjects: 62
Study 7870219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimens
Number of subjects: 62
Study 3422292 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation (EMS) applied for eight weeks post-surgery
Number of subjects: 23
Study 3422292 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 23
Study 3422292 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation (EMS)
Number of subjects: 23
Study 29431549 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced cycling (15 min daily for 15 months)
Number of subjects: 39
Study 29431549 — intervention group
Group type: COMPARATOR
Intervention: Recreational activities (control group)
Number of subjects: 39
Study 27803064 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (120 mg) with carboplatin and paclitaxel
Number of subjects: 158
Study 27803064 — intervention group
Group type: COMPARATOR
Intervention: Placebo with carboplatin and paclitaxel
Number of subjects: 158
Study 25673216 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring pressure (being watched by the experimenter)
Number of subjects: 0
Study 25673216 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 24144760 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil injection at 10 µg/d for 2 weeks
Number of subjects: 63
Study 24144760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with alprostadil injection at 10 µg/d for 2 weeks and oral beraprost sodium at 20 µg three times a day for 12 weeks
Number of subjects: 63
Study 24144760 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened sequential treatment with alprostadil injection at 20 µg/d for 2 weeks and double dose of oral beraprost sodium for 12 weeks
Number of subjects: 63
Study 24144760 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 63
Study 21563879 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml × 1 blood culture
Number of subjects: 258
Study 21563879 — intervention group
Group type: COMPARATOR
Intervention: 20 ml × 1 blood culture
Number of subjects: 258
Study 21563879 — intervention group
Group type: COMPARATOR
Intervention: 20 ml × 2 blood culture
Number of subjects: 258
Study 21563879 — intervention group
Group type: EXPERIMENTAL
Intervention: MB BacT culture
Number of subjects: 258
Study 21563879 — intervention group
Group type: COMPARATOR
Intervention: Isolator culture
Number of subjects: 258
Study 21563879 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 258
Study 18440489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal nerve excision
Number of subjects: 121
Study 18440489 — intervention group
Group type: COMPARATOR
Intervention: Ilioinguinal nerve preservation
Number of subjects: 121
Study 16476552 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartcanula (SC)
Number of subjects: 30
Study 16476552 — intervention group
Group type: COMPARATOR
Intervention: Control cannula (CC)
Number of subjects: 30
Study 12620603 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 0
Study 12620603 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (opioid antagonist)
Number of subjects: 0
Study 12620603 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (beta-blocker)
Number of subjects: 0
Study 12620603 — intervention group
Group type: COMPARATOR
Intervention: Atropine (muscarinic blocker)
Number of subjects: 0
Study 10994571 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs specifically prescribed for AD (tacrine, donepezil, and rivastigmine)
Number of subjects: 0
Study 9093045 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up by a specially trained nurse (intervention group)
Number of subjects: 168
Study 9093045 — intervention group
Group type: COMPARATOR
Intervention: Follow up by general practitioners (usual care group)
Number of subjects: 168
Study 9093045 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training programme (intervention group)
Number of subjects: 168
Study 8166473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (specific drugs not detailed)
Number of subjects: 0
Study 8166473 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agent etoposide
Number of subjects: 0
Study 8166473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of etoposide and cisplatin
Number of subjects: 0
Study 8166473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with hematopoietic growth factors
Number of subjects: 0
Study 2472242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide 1800 mg/day
Number of subjects: 20
Study 2472242 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg/day
Number of subjects: 20
Study 2472242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide 1200 mg + Metoprolol 200 mg
Number of subjects: 20
Study 2472242 — intervention group
Group type: COMPARATOR
Intervention: Tocainide 1800 mg + Metoprolol 200 mg
Number of subjects: 20
Study 951471 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback for increasing alpha activity
Number of subjects: 36
Study 951471 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback for suppression of alpha activity
Number of subjects: 36
Study 951471 — intervention group
Group type: COMPARATOR
Intervention: Rest periods without feedback
Number of subjects: 36
Study 31941707 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based dietary intervention with text messages
Number of subjects: 50
Study 31941707 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study 30150004 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein + CHO
Number of subjects: 20
Study 30150004 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein + LEU
Number of subjects: 20
Study 30150004 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein + CHO + LEU
Number of subjects: 20
Study 30150004 — intervention group
Group type: COMPARATOR
Intervention: Protein only
Number of subjects: 20
Study 28613284 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated and micronized zeolites (5.4 g once a day for 30 days)
Number of subjects: 85
Study 28613284 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg D‐alpha tocopheryl acetate once a day for 30 days)
Number of subjects: 85
Study 28613284 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (250 mg once a day for 30 days)
Number of subjects: 85
Study 25457497 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5mg once daily
Number of subjects: 82
Study 25457497 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 5mg twice daily
Number of subjects: 82
Study 25457497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dexamethasone 8mg twice daily on days 1-3 every 3 weeks
Number of subjects: 82
Study 25457497 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 82
Study 25457497 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 82
Study 25457497 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone after crossover from prednisolone
Number of subjects: 82
Study 23104724 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg/kg intetumumab
Number of subjects: 131
Study 23104724 — intervention group
Group type: COMPARATOR
Intervention: 75-mg/m2 docetaxel + 5-mg prednisone + placebo
Number of subjects: 131
Study 21977811 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM and Western medicine
Number of subjects: 62
Study 21977811 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 62
Study 19403231 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting from 1 to 10, repeated three times
Number of subjects: 48
Study 19403231 — intervention group
Group type: COMPARATOR
Intervention: Counting from 1 to 30
Number of subjects: 48
Study 17071254 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 104
Study 17071254 — intervention group
Group type: COMPARATOR
Intervention: Nonpropofol (Control)
Number of subjects: 104
Study 15296559 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous consultations
Number of subjects: 935
Study 15296559 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 935
Study 15296559 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel models
Number of subjects: 935
Study 11087152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low/stop corticosteroid regimen (half dosage for 3 months, then withdrawn)
Number of subjects: 500
Study 11087152 — intervention group
Group type: COMPARATOR
Intervention: Control corticosteroid regimen (standard dosage)
Number of subjects: 500
Study 11087152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low/stop corticosteroid regimen
Number of subjects: 500
Study 11087152 — intervention group
Group type: COMPARATOR
Intervention: Control corticosteroid regimen
Number of subjects: 500
Study 8520339 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes guidelines
Number of subjects: 24
Study 8520339 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma guidelines
Number of subjects: 24
Study 8520339 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured consultation prompts
Number of subjects: 24
Study 8520339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study 1904310 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAP II (hexamethylmelamine dosage‐intensive regimen)
Number of subjects: 0
Study 1904310 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAP I (hexamethylmelamine regimen)
Number of subjects: 0
Study 1904310 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage therapy with hexamethylmelamine
Number of subjects: 0
Study 1904310 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAP I & II (hexamethylmelamine‐containing regimens)
Number of subjects: 0
Study 1904310 — intervention group
Group type: COMPARATOR
Intervention: CHAP II
Number of subjects: 0
Study 6124495 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. Ranitidine 50 mg b.d. (or oral ranitidine 150 mg b.d. for up to 10 days)
Number of subjects: 50
Study 6124495 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative therapy
Number of subjects: 50
Study 30686305 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 150
Study 30686305 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 150
Study 28552382 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant 30 mg
Number of subjects: 121
Study 28552382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 25500324 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting reversible contraception (SARC)
Number of subjects: 917
Study 25500324 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraception (LARC)
Number of subjects: 917
Study 25500324 — intervention group
Group type: COMPARATOR
Intervention: Preference cohort (self-selected method use)
Number of subjects: 917
Study 25500324 — intervention group
Group type: COMPARATOR
Intervention: Randomized cohort
Number of subjects: 917
Study 24177484 — intervention group
Group type: EXPERIMENTAL
Intervention: Family adversity (domestic violence, family substance use, broken parental marriage)
Number of subjects: 5607
Study 24177484 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased family function
Number of subjects: 5607
Study 24177484 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of self-esteem
Number of subjects: 5607
Study 21433025 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.088 mg t.i.d. in week 1; 0.18 mg t.i.d. in week 2; 0.7 mg t.i.d. in week 3; 0.18 mg t.i.d. for 3 days and 0.088 mg t.i.d. for the rest of week 4)
Number of subjects: 40
Study 21433025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21433025 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 40
Study 19696778 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine (8-16 mg day(‐1))
Number of subjects: 29
Study 19696778 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichlormethiazide (1-2 mg day(‐1))
Number of subjects: 29
Study 17199066 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisource feedback intervention (n = 18)
Number of subjects: 36
Study 17199066 — intervention group
Group type: COMPARATOR
Intervention: Standard feedback only (Control group, n = 18)
Number of subjects: 36
Study 14994318 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined extract of Ginkgo biloba (120 mg) and Bacopa monniera (300 mg)
Number of subjects: 85
Study 14994318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 11474331 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CR)
Number of subjects: 18
Study 11474331 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 9738713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula
Number of subjects: 60
Study 9738713 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 60
Study 9817192 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 488
Study 9817192 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (10 mg twice or three times daily)
Number of subjects: 488
Study 2501265 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 41
Study 2501265 — intervention group
Group type: COMPARATOR
Intervention: Minocycline
Number of subjects: 41
Study 2501265 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline and Minocycline
Number of subjects: 41
Study 765388 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 42
Study 765388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42